Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases.
about
Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeuticsHeart failure in sub-Saharan Africa: review of the aetiology of heart failure and the role of point-of-care biomarker diagnosticsCardiac fibrosis in myocardial infarction-from repair and remodeling to regenerationRationale and design of a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of B-type natriuretic peptide for the preservation of left ventricular function after anterior myocardial infarctionNatriuretic peptides and the genomics of left-ventricular hypertrophy.Natriuretic Peptide testing in primary careBrain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agentA human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions.Effects of Low-Dose Recombinant Human Brain Natriuretic Peptide on Anterior Myocardial Infarction Complicated by Cardiogenic Shock.Plasma levels of matrix metalloproteinase 9 in patients undergoing off-pump coronary artery bypass grafting.Cardiac BNP gene delivery prolongs survival in aged spontaneously hypertensive rats with overt hypertensive heart disease.Chronic treatment with clenbuterol modulates endothelial progenitor cells and circulating factors in a murine model of cardiomyopathy.Remodeling of the heart in hypertrophy in animal models with myosin essential light chain mutations.Targeted disruption of guanylyl cyclase-A/natriuretic peptide receptor-A gene provokes renal fibrosis and remodeling in null mutant mice: role of proinflammatory cytokinesCD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart.Long-term effects of B-type natriuretic peptide infusion after acute myocardial infarction in a rat modelThe evolving role of nesiritide in advanced or decompensated heart failure.Essential biochemistry and physiology of (NT-pro)BNP.Can natriuretic peptides be used for the diagnosis of diastolic heart failure?Recent advances in natriuretic peptides in congestive heart failure.Predictive Values of N-Terminal Pro-B-Type Natriuretic Peptide and Cardiac Troponin I for Myocardial Fibrosis in Hypertrophic Obstructive Cardiomyopathy.The Effects of Velvet Antler of Deer on Cardiac Functions of Rats with Heart Failure following Myocardial Infarction.Relationship between Myocardial Extracellular Space Expansion Estimated with Post-Contrast T1 Mapping MRI and Left Ventricular Remodeling and Neurohormonal Activation in Patients with Dilated Cardiomyopathy.Preprocedural N-terminal pro-brain natriuretic peptide (NT-proBNP) is similar to the Mehran contrast-induced nephropathy (CIN) score in predicting CIN following elective coronary angiography.N-terminal proBNP: a novel biomarker for the diagnosis, risk stratification and management of congestive heart failure.The Gyc76C Receptor Guanylyl Cyclase and the Foraging cGMP-Dependent Kinase Regulate Extracellular Matrix Organization and BMP Signaling in the Developing Wing of Drosophila melanogaster.Mechanical stretch up-regulates the B-type natriuretic peptide system in human cardiac fibroblasts: a possible defense against transforming growth factor-β mediated fibrosis.N-terminal pro-brain natriuretic peptide levels and aortic diameters.The prognostic value of N-terminal proB-type natriuretic peptide.Role of calcium-activated potassium currents in CNP-induced relaxation of gastric antral circular smooth muscle in guinea pigs.Natriuretic peptides: novel therapeutic targets in heart failure.Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications.Membrane guanylyl cyclase receptors: an updateDifferential expression of the pro-natriuretic peptide convertases corin and furin in experimental heart failure and atrial fibrosis.Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide.Novel therapeutic directions for the natriuretic peptides in cardiovascular diseases: what's on the horizon.Long term follow-up report of cardiac toxicity in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation.Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP.Natriuretic peptide C receptor signalling in the heart and vasculature.B-type natriuretic peptide 8-32, which is produced from mature BNP 1-32 by the metalloprotease meprin A, has reduced bioactivity.
P2860
Q27004000-405C682D-E4AE-48AB-91AB-42B9E0CABE7BQ27015261-8F02715B-AAB2-46A5-A633-1E50AB83415CQ28068468-23A1E601-351E-4CBB-ACA7-7B4AD4955575Q30433780-D118D59E-E57A-4AC4-9530-A454CD54EFE3Q33516818-4BDBDB7A-0B27-47EC-B022-A1A14787C727Q33572286-6A0CA850-A39A-45AB-9AAE-AEE4C3ABE9CDQ33573360-A3E04890-19DF-4A16-A3A9-67C04A7C9DD3Q33577067-B99FA26C-87F5-44B0-8AF8-439BDCCE4F97Q33615284-2A65CD01-5DD8-467A-A942-B9C602F55AE2Q33639167-657E4CD1-EF8B-422F-AE6B-14476ECFF27FQ33657331-2791B36E-FA77-4330-B261-F786505DCE44Q33789760-56E36D76-E4AB-4A53-9B5A-F2CA42396C36Q34219487-408A95F1-150B-4C22-BF48-A74C8A00BA24Q34392664-6FDF6BEB-D8F1-4D64-B89C-F7C3ED8E4E37Q34526136-5C7247CE-BD28-49DB-BADD-040A29CC0943Q34891600-4B66AB86-4BE9-41FE-BC8E-08688434FDF7Q35574016-DD3CCF93-B39D-4C09-BF79-4E4034FFF50BQ35677297-776695AF-1821-416D-A2F9-96FB9C3A8DCBQ35677306-8F315F1F-17D9-4F7B-8ABA-E1A6274CDC27Q35790792-5DD303E0-7CA1-4140-93CD-A2DFD9B5F120Q35893689-46C6DAFF-88BB-4186-9EF9-F263E3AAF67DQ35948128-148ED3F5-8A09-4CE3-AA25-3458C0F62A8DQ36026885-C24C65B1-A8CB-4D02-9FE6-F4D88B382427Q36085790-DB5B71DD-3F51-4FBB-A455-FB481BC6DA40Q36124913-CB96FF0B-4E0D-483E-9F1C-CFBFE6897C21Q36126757-5C95DE93-E89F-426C-A018-FBEF9E3FFA65Q36138885-2E5D2CA3-0DEC-4576-B457-254C2C7CACB5Q36254265-948AB5F8-6C6B-476A-AEF6-E14CEE6D7A6AQ36304293-28CEF0E5-0422-41AF-8837-8BB74A429C24Q36309245-8BB8DB29-4777-4100-AE04-6FBD09A1731CQ36317213-6124F6FF-8B4A-49DD-8770-430A6259D321Q36350919-B963D859-0819-45F0-9BDD-FC9A738533C4Q36525043-4701B014-F565-44BB-864E-9E230BF93A18Q36528021-2F19537E-01B4-4320-A144-D9682A311C3FQ36564032-D3C7D9DE-5B3D-4ABD-90A8-12A49B68EEBCQ36669295-72683431-7B05-4413-9598-2AC08ABF0DD3Q36951074-D4CD6CAF-8798-40D4-94B5-B47812664D93Q36954799-51F812A0-BC63-434C-961C-4D214679FF24Q37002318-93CF39DF-2CE4-4788-AE5D-3BA296053743Q37217952-D8999EE1-3789-4838-A497-6C1F7CCB3FDD
P2860
Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Brain natriuretic Peptide is p ...... ces matrix metalloproteinases.
@en
Brain natriuretic Peptide is p ...... ces matrix metalloproteinases.
@nl
type
label
Brain natriuretic Peptide is p ...... ces matrix metalloproteinases.
@en
Brain natriuretic Peptide is p ...... ces matrix metalloproteinases.
@nl
prefLabel
Brain natriuretic Peptide is p ...... ces matrix metalloproteinases.
@en
Brain natriuretic Peptide is p ...... ces matrix metalloproteinases.
@nl
P2093
P1433
P1476
Brain natriuretic Peptide is p ...... ces matrix metalloproteinases.
@en
P2093
Alessandro Cataliotti
Brenda K Huntley
Guido Boerrigter
Horng H Chen
John C Burnett
Josh A Noser
Lisa C Costello-Boerrigter
Toshihiro Tsuruda
P304
P356
10.1161/01.RES.0000046234.73401.70
P577
2002-12-01T00:00:00Z